Lymphoma

Latest News

In lieu of an 8-to-1 ODAC ruling against the applicability of the phase 3 STARGLO results in US patients, a CRL has been issued for glofitamab in relapsed/refractory DLBCL.
FDA Issues CRL to Glofitamab Plus GemOx in ASCT-Ineligible R/R DLBCL

July 21st 2025

In lieu of an 8-to-1 ODAC ruling against the applicability of the phase 3 STARGLO results in US patients, a CRL has been issued for glofitamab in relapsed/refractory DLBCL.

Unpacking the EPCORE NHL-1 Trial and Epcoritamab’s Promise in R/R LBCL
Unpacking the EPCORE NHL-1 Trial and Epcoritamab’s Promise in R/R LBCL

July 3rd 2025

Data support incorporating volumetric PET biomarkers into toxicity risk prediction for patients receiving CAR T-cell therapy for LBCL.
High Tumor Volume Confers CAR T-Cell Therapy Toxicity Risk in LBCL

June 30th 2025

FDA Removes REMS, Lessens Requirements of Liso-Cel/Ide-Cel in Blood Cancers
FDA Removes REMS, Lessens Requirements of Liso-Cel/Ide-Cel in Blood Cancers

June 27th 2025

This case report explores the diagnosis and treatment of extranodal NK/T-cell lymphoma, highlighting clinical challenges and advancements in pathology and therapy.
Extranodal NK/T-Cell Lymphoma Misdiagnosed as Pulmonary Infection

June 25th 2025

Latest CME Events & Activities

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

View More

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

View More

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

View More

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

Community Practice Connections™: Selecting and Sequencing Therapy for Patients with DLBCL in an Era of Expanding Options

View More

BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD

View More

(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

View More

(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

View More

Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

View More

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

View More